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Abstract
Objective: To systematically identify from qualitative data in the published literature the main barriers to adherence to
isoniazid preventive therapy (IPT) for tuberculosis (TB) among people living with HIV/AIDS (PLWHA).
Methods: We searched ten data sources, including MEDLINE and EMBASE for articles published in peer-reviewed journals
from inception through to December 2011 for evidence relevant to IPT for TB in relation to PLWHA. Studies were assessed
for quality using the CASP critical appraisal tool for qualitative studies. Data extracted from studies were then analysed
thematically using thematic synthesis.
Results: Eight studies, two of which were conducted within the same clinical trial, met the inclusion criteria. In addition to
the influence of personal characteristics, five overarching themes were identified: Individual personal beliefs; HIV treatment
and related issues; Socio-economic factors; Family and other social support factors, and Relationships with health providers.
The review confirms current understanding of adherence to treatment as influenced by patients’ understanding of, and
beliefs related to treatment regimens. This is in-turn influenced by broader factors, namely: socio-economic factors such as
poverty and lack of health facilities; the level of support available to patients from family and other networks and the stigma
that emanates from these relationships; and relationships with health providers, which in-turn become a delicate issue
given the sensitivity of dealing with two chronic diseases of significant morbidity and mortality toll. HIV treatment related
issues also influence adherence to IPT, whereby challenges related to the acceptance, organisation and administration of
these two long-term treatment regimens and stigma related to HIV/AIDS, are seen to be major factors.
Conclusion: Understanding this complex interplay of factors more clearly is essential for healthcare decision-makers to be
able to achieve the level of adherence required to effectively mitigate the threat posed by co-infection with TB and HIV/
AIDS in developing countries.
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Introduction
Tuberculosis (TB) is the most common opportunistic infection
and leading cause of mortality in people living with HIV/AIDS
(PLWHA). In PLWHA, the risk of developing TB is 21–34 times
greater than those without HIV infection [1]. Globally, around 1.1
million people were estimated to be co-infected with HIV and TB
in 2010, representing in excess of 10% of the 9 million new cases of
TB that year [1]. This overall trend differs according to the state of
the HIV epidemic in different settings. In hard hit areas such as
Sub-Saharan Africa (where there is a generalized HIV epidemic),
PLWHA represent around 39% of new TB cases [1]. Co-infection
with HIV and TB resulted in some 0.35 million TB attributable
deaths amongst people living with HIV worldwide, in the year
2010 [1].
The interaction between HIV and TB is bidirectional with each
disease potentiating the adverse effects of the other. This, in turn,
affects the prognosis of patients and complicates clinical diagnosis
and treatment plans through atypical presentation of symptoms,
adverse drug reactions, overlapping drug toxicities and drug-drug
interactions between Highly Active Anti-Retroviral Therapy
(HAART) and anti-TB drugs [2,3,4]. Co-infection with HIV
and TB adds significantly to the burden on health systems in the
developing world and complicates and threatens efforts aimed at
achieving globally set development and health objectives [2,3,4,5].
Isoniazid preventive therapy (IPT) for people living with HIV,
who do not have active TB, is one of the strategies recommended
by the World Health Organization (WHO) and the Joint United
Nations Programme on HIV/AIDS (UNAIDS) to enable the
effective prevention, diagnosis and treatment of TB in PLWHA
PLOS ONE | www.plosone.org 1 February 2014 | Volume 9 | Issue 2 | e87166
[6,7,8]. The recommended regimen for TB preventive therapy in
adolescents and adults is isoniazid (isonocotic acid hydrazide –
INH), 300 mg daily for at least 6 months [8,9]. A Cochrane review
assessing the effectiveness of TB preventive therapy in reducing
the risk of active TB and death in persons infected with HIV,
‘confirms that chemoprophylaxis with anti-tuberculosis drugs
reduces the risk of clinical tuberculosis in HIV infected popula-
tions’ [10]. The review also cautions about the dangers of ‘poor
adherence and drug resistant TB disease potentially associated
with the use of long courses of isoniazid monotherapy’ [10].
Various health system related constraints have impeded the
uptake of IPT. Only 12% of PLWHA who were newly enrolled in
HIV care programmes were started on IPT, worldwide, in 2010
[1,9]. Adherence to treatment is a critical factor that needs to be
considered in scaling up services in developing countries [9,10,11].
This paper seeks to systematically review the evidence on
adherence to IPT with a view to assessing and interpreting
deterrent and enabling factors associated with observed trends in
non-adherence.
Methods
Search strategy
The P-population I-Intervention C-Comparator O-Outcome
framework is commonly used for determining inclusion and
exclusion criteria for systematic reviews of quantitative studies
[12]. For this review of qualitative data, a counterpart labelled as
the ‘SPICE framework’ [13] was modified to formulate the review
question. SPICE stands for S-setting, P-perspective, I-intervention,
C-comparator and E-evaluation and specifies the key attributes of
the review question (Table 1).
We developed a highly sensitive search strategy combining key
terms that may indicate the use of isoniazid (e.g. isoniazid/e),
combined with the concept of adherence (e.g. adheren* OR
complian*) and with an indicator of data required (e.g. qualitative
OR findings OR interview*). This broad search strategy for
qualitative data has been shown to perform acceptably when
compared with more exhaustive lists of qualitative terms [14,15].
Because the search was intended to be as sensitive as possible we
did not restrict by population at the searching stage. Instead we
established an explicit association of relevant papers with both
HIV/AIDS and TB when sifting by title and abstract. Initial
searches were developed (T.M.) for the following sources from
inception to August 2011: Ovid MEDLINE, Embase, PubMed,
CINAHL via Ebsco, Cochrane Central Register of Controlled
Trials (Central), Scopus, Proquest, Web of Knowledge, Google
and Google Scholar. Subsequently, a qualified and experienced
information professional (A.B.) constructed a series of supplemen-
tary search strategies and methods to validate the initial retrieval
set and to extend data coverage until December 2011. This
process, which involved subject searching of MEDLINE and Web
of Science and citation searches for included studies on Web of
Science and Google Scholar, identified two additional recent
studies. The search strategy for MEDLINE on OvidSP is provided
as supporting information: Ovid MEDLINE Search strategy,
Table S1. Our search was complemented by reviewing reference
lists of relevant papers.
Study selection
One investigator (T.H.) performed a preliminary scan of titles
and abstracts for eligibility according to predefined inclusion
criteria. Final decisions, for confirmation or in cases of uncertainty,
were resolved in discussion with a second investigator (H.B.T).
Title and abstracts from supplementary searches, identified by
A.B. were examined by both the investigators (T.H. and H.B.T.)
and an authoritative decision on inclusion was made jointly
according to the original inclusion criteria. Once all potentially
relevant full-text articles and abstracts were identified, we
consulted as a team (T.H., H.B.T., A.B.) to achieve consensus
regarding final eligibility.
Data extraction
Initial data extraction was conducted independently, using a
standardized form (T.H) and then verified by a second reviewer
(A.B.). Subsequent tabulation was verified by a third investigator
(H.B.T.). Data abstractors collected information about the study
setting, study populations, sample size, dosage, and any mecha-
nisms for ensuring adherence. Our primary interest was in
verbatim responses from informants on barriers to their adherence
with isoniazid preventive therapy. However we were also
interested in patient responses to pre-identified factors, for
example in structured surveys or questionnaires. For triangulation
purposes only we also decided to include reports from health
personnel when in direct contact with patients and who, therefore,
had perceptions on reasons for adherence/non-adherence. How-
ever these were treated as ‘‘indirect evidence’’ only and, therefore,
were not used to direct our initial conceptual model. We applied
the Critical Appraisal Skills Programme (CASP) checklist for
qualitative studies, as adapted by Hawker and colleagues, since it
can also be used in studies where disparate data are involved [16].
The nine detailed questions were answered according to the
responses; Good, Fair, Poor and Very Poor to arrive at an overall
qualitative judgement on study quality.
Data synthesis
Several alternative methods exist for synthesis of qualitative
data. Where studies contain conceptually-rich data and the
objective is to improve theoretical understanding, more interpre-
tative methods, such as meta-ethnography, are available. Howev-
er, the output of some methods of synthesis, (e.g. thematic
synthesis and framework synthesis), is considered more directly
relevant to policymakers and designers of interventions than
outputs from methods with a more constructivist orientation (e.g.
meta-ethnography) which are generally more ‘‘complex and
conceptual’’ [17]. Thematic synthesis is analogous to methods of
primary analysis of qualitative data such as thematic analysis,
using techniques to formalize the identification and development
of themes [18]. Such themes can be explored both individually
and in terms of their inter-relationships with each other. Thematic
synthesis was therefore used to analyse factors relating to
adherence with isoniazid preventive therapy in people living with
HIV/AIDS.
Table 1. SPICE formulation for the question.
Setting(s): Hospital or clinics administering IPT
Perspective: People living with HIV/AIDS (PLWHA)
Intervention: Isoniazid preventive treatment
Comparison: None
Evaluation: Factors that contribute to IPT adherence
doi:10.1371/journal.pone.0087166.t001
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Results
Figure 1 shows the flow diagram of study selection for analysis.
Furthermore, the nine studies excluded at the final stage of the
selection process, after assessment of the full text articles, are
presented in table 2, along with the reasons for exclusion.
Settings and Populations
The eight included papers [19,20,21,22,23,24,25,26] were
published between 1997 and 2011 and were conducted in
Botswana [20,22], Ethiopia [21], South Africa [25,26], Tanzania
[19,23], and Thailand [24]. Close examination revealed that two
of the studies were based on data from the same clinical trial that
sought to ‘determine whether continuous isoniazid is superior to a
6 month course…’ [20,22]. The earlier published paper is a
secondary analysis of trial records and its objectives related to
adherence were to find correlations between observed adherence
rates on the one hand, and patient characteristics and influences of
ART on the other [22]. The latter published paper involved
administration of surveys and focus group discussions and in-depth
interviews amongst a sample of adherents and non-adherents [20].
Data from both papers were therefore extracted for this synthesis.
Details of data extracted from all studies are presented in tables 3
and 4.
The eight studies employed qualitative and quantitative
methods as well as mixed method designs. This synthesis focuses
primarily on the qualitative data. PLWHA were recruited from in-
and outpatient hospitals and clinics providing TB preventive
treatment [20,21,22,25,26], from a cohort of PLWHA participat-
ing in a TB vaccine trial [23], HIV screening services for different
population groups such as blood donors, counselling service users
and those attending the routine provider initiated HIV Counsel-
ling and Testing Service (HCT) [24], as well as from cohort studies
focusing on specific population groups such as commercial sex
workers [24] and police officers [19]. Participants were screened
with Tuberculin Skin Testing (TST) for TB infection before
enrolment and were excluded if they had a history of TB or if they
were hypersensitive to TST. Sputum examination for acid fast
bacilli (AFB) and chest radiograph were performed in each case
except for one study [20], where insufficient details were provided.
Informed consent was obtained for each participant. One study
involved commercial sex workers and blood donors [24], another
involved police officers [19] while the others involved general
populations of PWLHA.
A total of 4,228 patients were involved in the studies ranging
from 87 to 1995 patients, with two studies [22,23] having in excess
of 500 patients. The basic demographic characteristics of study
subjects were reported variably in the included studies. The sex
distribution of study subjects was reported across the studies,
whereby 2,796 (66%) of the total study population were females.
The mean age was reported in (or could be retrieved from) the
studies by Bakari et al [19], Gust et al [20], Mindachew et al [21],
and Szakacs et al [26] as 38, 35, 35 and 33 years respectively. On
the other hand, Mosimaneotsile et al [22] and Munseri et al [23]
reported the median age in their study as 32 years. Ngamvithaya-
Figure 1. PRISMA flow diagram of selection of studies.
doi:10.1371/journal.pone.0087166.g001
Adherence to Isoniazid Preventive Therapy
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e87166
pong et al [24] and Rowe et al [25] reported proportions of the
study population within specified age groups whereby those above
35 years of age accounted for contrasting proportions of 15 and 77
percents, respectively.
For the studies that reported the marital status of study subjects
[19,21,22,24], 44% of respondents were married at the time of the
survey. For studies that reported the employment status of study
subjects [20,21,22,23], the pooled proportion for unemployed
subjects is found to be around 30%. While Ngamvithayapong et al
report the employment status of their study population; they
basically just report the proportion of those who are self employed
(46%) and those employed by others (54%). As for the studies that
reported educational status, the proportions of those who had a
secondary level education or more were reported at more than
55% by three studies [20,21,22] while one study reported this at
just 22% [24]. Other basic demographic characteristics reported
in the studies include: monthly income, in variable currencies, by
Mindachew et al in USD [21] and Gust et al in Botswana Pula
[20]; Body Mass Index, only by Gust et al [20]; and distance to
clinic, using variable measures of, ‘time to clinic’ by Gust et al [20]
and subjective reports of how far respondents felt the clinics were,
by Ngamvithayapong et al [24]. As such, the demographic
characteristics were not reported in a standardised fashion across
the studies and are only summarised here to add to the contextual
understanding of the synthesis presented in this review.
Study characteristics
Studies rated as better quality gave an in-depth account of the
qualitative design used and the subsequent method of analysis
[20,25]. The apparently relatively poor quality of some studies was
directly attributable to the poorer quality of their reporting
[23,24]. All studies performed well for applicability, with the
exception of one study which was limited to a police officer
population [19]. The utility of this particular study was further
limited in only including analysis of factors for acceptance of
enrolment in IPT and not factors for adherence or non adherence
after commencement of the medication. Quality assessment of
qualitative research studies is currently a contested area, with even
poor quality studies potentially offering useful insights [18], so a
decision was made not to exclude any studies on the basis of study
quality alone. Table 5 shows the assessment of the methodological
quality of included studies.
Intervention
IPT was given to all participants orally for 6 months except in
one study [24] where the duration was 9 months. Most studies
stated that participants were prescribed with 300 mg INH except
for one study [20] which did not state the amount given. Typically,
participants were required to collect their drug supply on a
monthly basis and were instructed to bring any left-over pills for
assessment.
Outcomes
Different strategies were used to assess adherence. Adherence
was defined as self reported adherence over the last 7 days
(reported adherence, 86.5%) [21], adherence to at least 80% of
scheduled clinic visits for medicine refill (reported adherence, 78%)
[20], completion of entire 6 months regimen of IPT in two studies
[22,23] (reported adherence, 87%, for both studies), urine tests for
isoniazid metabolites (reported adherence, 72%) [26], taking more
than 80% of pills (reported adherence, 65.5%) [19], patterns of pill
collection (reported adherence, 47.1%) [25], and based on the 216
pill count cut off point (reported adherence, 67.5%) [24].
Accordingly, adherence rates ranged between 47.1% and 87%.
Themes
Thematic synthesis involves identification of similar themes,
organization of these similar themes into related areas and the
development of analytical themes [17]. Major themes are
constructed by reflecting, reading and re-reading, comparing,
and interpreting the primary identified themes. Such major
themes include verbatim data from respondents and interpreta-
tions put forward by the authors of included studies. Following
critical analysis, all primary themes were categorized into sub-
themes based on the review findings. Findings from this qualitative
Table 2. Excluded studies with reasons for exclusion.
Excluded studies Reason(s) for Exclusion
Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Churchyard
GJ. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South
Africa: a novel randomized incremental recruitment study. JAMA. 2005 Jun 8;293(22):2719–25.
No adherence related data
le Roux SM, Cotton MF, Golub JE, le Roux DM, Workman L, Zar HJ. Adherence to isoniazid prophylaxis among
HIV-infected children: a randomized controlled trial comparing two dosing schedules. BMC Med. 2009; 7:67.
Not Adult perspective
Okanurak K, Kitayaporn D, Akarasewi P. Factors contributing to treatment success among tuberculosis
patients: a prospective cohort study in Bangkok. Int J Tuberc Lung Dis. 2008;12(10):1160–5.
Adherence to IPT was not assessed
Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R. INH preventive therapy among
adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis. 2005 Mar;9(3):270–5.
Only tests significance of Tuberculin Skin Testing
(TST) as a factor in adherence
Lertmaharit S, Kamol-Ratankul P, Sawert H, Jittimanee S, Wangmanee S. Factors associated with compliance
among tuberculosis patients in Thailand. J Med Assoc Thai. 2005;88 Suppl 4:S149–56.
Adherence to IPT was not assessed
Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, Grant AD. Barriers to
implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS. 2010;24 Suppl 5:S45–8.
Only studies barriers to implementation
Nuwaha F. Factors influencing completion of treatment among tuberculosis patients in Mbarara District,
Uganda. East Afr Med J. 1997;74(11):690–3
Reported elsewhere
O’Brien RJ, Perrie¨ns JH. Preventive therapy for tuberculosis in HIV infection: the promise and the reality. AIDS.
1995;9(7):665–73.
Case report
Souza CT, Ho¨kerberg YH, Pacheco SJ, Rolla VC, Passos SR. Effectiveness and safety of isoniazid
chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. Mem Inst Oswaldo Cruz. 2009;104(3):462–7.
No analysis of factors for non-adherence
doi:10.1371/journal.pone.0087166.t002
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systematic review can be organised under five different overarch-
ing themes; (i) individual personal beliefs; (ii) HIV treatment and
related issues; (iii) socio-economic factors; (iv) psychosocial and
family factors, and (v) relationships with health providers (Table 6).
Of these themes, only theme (ii), that is, HIV treatment and
related issues, was specific to this particular population, when
compared to a general population with TB [27]. Some issues, such
as stigma, may be compounded where a patient has HIV in
addition to TB, but conceptually the array of issues is similar.
‘HIV treatment and related issues’ is therefore prioritised within
the following description of the themes, in order to highlight the
unique contribution of this review.
Theme one: Individual personal beliefs
Five studies [20,23,24,25,26] described individual personal
beliefs as core factors contributing to the adherence of IPT. Such
individual personal ‘‘micro-level’’ beliefs include fear of INH side
effects, understanding of IPT and its importance, and belief in
INH safety. Three studies [24,25,26] focused on patients’
understanding of the effect and the repercussions of defaulting
or not adhering to IPT treatment. Other related reasons include
misunderstanding about the duration of IPT which also highlights
the importance of counselling prior to enrolment [24]. However
Ngamvithavapong and colleagues also observe that patients were
successful in adhering even though they lacked accurate knowl-
edge [24]. This is shown in the following statement:
‘Some of them [adherents] thought that Isoniazid reduced blood HIV
concentration or that it prevents other AIDS-related complications’ [24]
Theme two: HIV treatment and related issues
HIV treatment and related issues such as concurrent use of
HAART and denial of HIV status posed further contributing
factors towards non-adherence to IPT. Patients in included studies
reported feeling discouraged to take two regimens at the same
time. They also described how they experienced toxicities, felt
their disease was too advanced to be cured or did not want to be
associated with the HIV ‘‘stigma’’ [20]. Denial or non-disclosure
of HIV status was the most common of all sub-themes identified
from the selected studies. This was a major theme in two studies
[20,25], as fear of rejection and stigmatization prevented people
from disclosing their HIV status or coming out for treatment. This
is confirmed both by author interpretation and by direct
quotations from participants:
The reason for this difference may be that, in our setting,
IPT is linked to HIV, and women in this study did not want
their HIV status to be disclosed due to fear of separation
from their spouses or families. [23]
‘It’s not good to tell anyone … because it’s spread all over the village. So
I’ll be having a problem because I won’t be free when I go around. I’ll
be afraid of the people’ (interrupter) [25]
Beyond the influence of HIV related stigma, Rowe and
colleagues draw upon a host of observations related to people’s
understanding and interpretation of HIV/AIDS as an illness, what
they call, ‘an individual’s health culture’ [25]. This relates to the
perception of HIV/AIDS as incurable and the associated tension
between people’s faith in western medicine on the one hand and
traditional healing practices on the other, which especially come to
a head in the case of such ‘fatal’ diseases [25].
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‘‘Members of the church are taught that they cannot combine the clinic
medication with the (church tea)’’ [25]
Switching to herbal medicine was also amongst reasons for non
adherence discussed by participants in the study by Ngamvithaya-
pong and colleagues [24]
Theme three: Socio-economic factors
Socioeconomic factors were frequently associated with barriers
to adherence. One aspect to this is the competition from other
social and economic responsibilities. Participants in included
studies describe the difficulties of maintaining a regular drug
supply when required to participate in harvesting, military service
or physically distant employment. Participants were more likely
not to appear for treatment in cases where they had to seek
permission from their employers. One participant suggested:
‘‘Even the bosses should be told about this program so that tomorrow
when people ask for permission for these visits every month, they should
know what is going on.’’ [20]
Gust et al also state that, ‘themes associated with barriers to trial
participation included, for example, competing commitments…and relocation’.
[20]
Four studies [20,23,25,26] highlighted that patients experienced
problems in accessing TB treatment because of distance, location
of hospital or clinic, and non-availability of service providers.
Conversely, participants in one study [25] gave instances of where
the clinic environment positively influenced adherence because of
its seclusion and privacy from other public places:
‘‘The fact that the clinic is private and separate from the general
outpatient clinic, I can explain everything that is confidential and secret
to me. It’s a good place’ (new patient)’’ [25]
Theme four: Family and other social support related
factors
Family and other social support related factors mainly include
the nature of relationships with family members, the wider
community, and others taking IPT, as well as the adverse effects of
stigma that emanates from these relationships [25]. Relationships
with family and friends appear to determine whether patients feel
comfortable about taking IPT [20]. Stigma may also make patients
ashamed to ask their employers for permission to attend their TB
treatment. This impedes early treatment and facilitates progression
of Latent to Active TB [24]. In some families, responsibilities of
parenthood could work as a motivating factor to adhere to
treatment while others reported that responsibilities such as taking
care of children could reduce the possibility of adherence [26].
Support and encouragement from spouse, family and community
health workers and concern for family members facilitated
adherence to IPT as exemplified by the following data extracts
from included studies:
Some said that they were concerned about their children
and family, and these concerns motivated them to prolong
their life including the taking of Isoniazid [24]
‘I feel relieved just because I find myself with other people
who are sick. We have this illness together’ [25]T
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Table 6. Major and sub-themes identified from included studies.
Theme/Subtheme Sample Data
1. Individual personal beliefs
a. Fear of INH side effects, Perceived side effects of isoniazid [25]
Side effects of the study medication (but personal doctor did not tell me to stop) [21, p. 7]
I always felt like vomiting and my eyes were always itching because of the pills.’’ [21, p. 4]
b. Perceptions of HIV People have noticed that everywhere they go, it says ‘HIV kills’. So even if I take treatment, I am not going to be
cured. I am going to die …so that’s why people cannot take treatment regularly’ [26, p. 266]
c. Belief in INH safety 22% agreed that INH is dangerous to your health [27, p. 5]
Those who believed that INH was safe were less likely to have a negative urine test [27, p. 3]
d. Fear of TB/HIV complications The 109 interviewed completers cited the following factors in their decision to complete IPT: fear of TB (n = 48,
44%)… fear of TB and HIV complications (n = 24, 22%) [24, p. 1039]
e. Knowledge of IPT importance Misunderstanding about duration of the preventive therapy [25]
Despite having completed the 9 month programme, about a quarter of the participants still did not know about the
effect of isoniazid in preventing clinical TB [25]
f. IPT understanding ‘‘I have completed the 9-month IPT programme and I do not know the effect of Isoniazid in preventing clinical TB, I
think Isoniazid is dangerous to my health’’ [27, p. 4]
g. Being asymptomatic ‘Since last year I took the tablets for TB. Then I find I feel better, and I don’t take the tablets. And even this year I took
another package for TB. But when I feel better, I don’t drink the tablets. Only when I feel pain.’ [26, p. 266]
Health worker: ‘Really a person can’t take medicine when he’s not sick’ [26, p. 266]
h. Forgetting Forgetfulness [22]
Patients who reported they sometimes forget to take the INH were more likely to have negative tests [27,p. 4]
2. HIV treatment and related issues
a. Denial of HIV status Denial of HIV status [25]
b. HIV disclosure ‘It’s not good to tell anyone…because it is spread all over the village’ [26, p. 265]
c. Concurrent use of HAART ‘‘I was taking a lot of tablets and I was always thinking I will die…so I decided to stop these ones (isoniazid).’’ [21, p. 4]
d. Alternative treatments ‘They think that if they go to the traditional healers, they will give them something to drink. They are given a
medicine, they think they will be cured.’ [26, p. 266]
e. Pill Burden Taking too many pills [21, p. 7]
3. Socio-economic factors
a. Out-migration for employment and
competing work priorities
Out-migration for job search in other provinces [25, p. 110]
‘‘My job contract came to an end and I had to relocate to my home village’’ [21,p. 4]
‘‘The reasons were work commitments. My job was a barrier to taking the pill but the medication treated me well.’’
[21, p. 4]
Many noted competing needs and priorities at home in relation to subsistence issues for themselves and their
families. [26, p. 265]
b. Economic resource limitations ‘It’s the money that can make people come and take tablets. Because of the distance, because people cannot just
walk to the clinic, because you have to come every month … So if people can have money, there will be no problem.’
[26, p. 265]
The limited resources available to this rural population were universally cited as a barrier to adherence [26, p. 265]
Patients cited the need to use public taxis and the associated financial costs as a significant obstacle. [26, p. 265]
c. Economic dependence on family People who depended on their parents or husbands for financial support, namely adolescents and women, remarked
that the decision to come to the clinic was not entirely their own. One young woman stated: ‘It is difficult sometimes
when my parents say they don’t have money to give me to come to the clinic, for transport’ (new patient). [26, p. 265]
When asked why she had difficulty coming to the clinic, another interrupter answered: ‘It was one day when I didn’t
come to the clinic because I didn’t have the money to come.’ [26, p. 265]
Young woman: ‘It is difficult sometimes when my parents say they don’t have money to give me to come to the clinic,
for transport’ [26, p. 265]
Distance from home to clinic ‘‘We need to have a number of dispersed clinics so that people who are residing in rural areas get the medical
services they need at the right times.’’ [21, p. 5]
‘‘When you are far from the clinic, the transport to the clinic becomes a problem.’ [21]
Because of the distance, because people cannot just walk to the clinic, because you have to come every month…[26,
p. 265]
Location of drug supply ‘‘The fact that the clinic is private and separate from the general outpatient clinic, I can explain everything that is
confidential and secret to me. It’s a good place’ (new patient)’’. [26, p. 266]
4. Family and other social support related factors
a. Stigma/Double stigma It’s not good to tell anyone … because it’s spread all over the village. So I’ll be having a problem because I won’t be
free when I go around. I’ll be afraid of the people’ (interrupter) [26, p. 265]
‘‘They (Botswana) still discriminate against people on the trial and that discrimination is what makes people drop out
of the trial.’’ [21,p. 4]
b. Concern about family Some said that they were concerned about their children and family, and these concerns motivated them to prolong
their life including the taking of isoniazid. [25, p. 111]
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Theme five: Relationships with health providers
The reception received by participants when attending health
services [25], including whether effective communication takes
place [20], has a major impact on the patient’s adherence to
treatment. Several extracts relate to the relationship with health
providers, specifically in terms of the nature of the advice, and
whether it’s given or not given [21]. Rowe and colleagues reported
that individuals most likely to benefit from HIV-related clinical
interventions were those who were already users of health services
[25]. They concluded that substantial challenges remain amongst
those reluctant to present for testing, care, and support. In some
cases, recruitment in a study may result in conflicting advice
between the study personnel, who advocate compliance, and a
personal physician who expresses reservations about the treatment
[20]. Clearly such a tension juxtaposes a new and contingent
relationship against a longstanding, perhaps even lifelong
relationship with a personal doctor. Such a situation may be
exacerbated where belief in the effectiveness of treatment is limited
and patients are encouraged, either by family members or by
others in the community, to explore more traditional alternative
treatments [25].
Framework for explaining factors influencing IPT
adherence
A model adapted and modified from Munro and colleagues
represents how factors interact to influence IPT adherence [27]. A
key interaction occurs between individual personal beliefs and
family and social support factors; where patients’ interactions with
family and the wider community, including health workers
(relationships with health providers), influence their knowledge,
attitudes and beliefs about IPT treatment. Socio economic factors
are likely to influence individual personal beliefs, especially where
patients live far from clinics and have fewer opportunities to be
enlightened about the benefits of IPT. Similarly, HIV treatment
and related issues affect patients’ response to IPT treatment;
whereby patients would not be likely to adhere to IPT treatment if
they are not willing or able to disclose their HIV status. Figure 2
illustrates how the five major themes interact.
Integrating the Qualitative data with Quantitative data
As clearly evidenced in Table 1, included studies also collected
quantitative data. When making informed decisions, local policy-
makers need to examine a mix of quantitative and qualitative
evidence. The high heterogeneity of the quantitative data, both in
terms of methodological and statistical heterogeneity, does not
allow the pooling together and/or meta-analysis of reported
outcomes. In this respect, the included studies are found to be
highly variable in terms of: their definition of the outcome measure
(adherence rate); the demographic characteristics and other factors
they report and analyse; and whether they report demographic
characteristics by outcome (adherent versus non adherent groups).
Still, while preserving the qualitative focus of our review, the team
believes that it would be helpful to ‘‘triangulate’’ the thematic
analysis with this quantitative data. Hence, the various factors in
our model (Figure 2) are consequently revisited here to corrob-
orate findings from the qualitative synthesis. Although the
quantitative data are selective in the topics that they specifically
address and, particularly, derive from a limited number of
included studies, they do provide a mechanism for exploring the
robustness of the synthesis [28].
Personal characteristics
Personal factors related to people’s characteristics such as age
and sex are believed to have a major influence on their adherence
behaviour. Gust and colleagues observed that the case non-
adherent group was younger (t = 58.2, P,0.0001), and included a
Table 6. Cont.
Theme/Subtheme Sample Data
c. Instrumental support from
another family member
‘‘I have an aunt in (a neighboring township). She is a businesswoman. She’s the one who is taking care of me, she’s
helping me and she is very supportive of me even to come to the clinic, to join the support group, she’s the one who
motivated me to come here…. She gives me nutritious food’’ [26, p. 266]
‘So those who stop, it’s because they don’t have someone who is taking care or controlling their treatment’ [26,
p. 265]
d. Support group ‘I feel relieved just because I find myself with other people who are sick. We have this illness together.’ [26, p. 266]
e. Family responsibilities Many noted competing needs and priorities at home in relation to subsistence issues for themselves and their
families [26, p. 265]
f. Other social factors Members of the church are taught that they cannot combine the clinic medication with (church) tea: She’s got days
for tablets and days for tea, not at the same time.’ [26, p. 266]
5. Relationships with health providers
a. Clinic Environment The fact that the clinic is private and separate from the general outpatient clinic helped to reduce patients’ fear of
stigmatisation: ‘But now, I can just explain everything that is confidential and secret to me. It’s a good place’ [26,
p. 266]
‘…They [completers] were satisfied with the service and the providers’ [25]
b. Service availability Drug supply: An alarming level of peripheral pharmacies are reported to run out of medications, which may impair
overall adherence [27, p. 5]
c. Health provider relationship The importance of supportive nurses for adherence was mentioned by almost all the completers, and their
sentiments are summarized in the words of one woman who said: ‘… So again when I visit the clinic, I feel nice when I
visit the clinic. Because when I get here they motivate me, encourage me not to think about it (HIV status) and the
nurse tells me everything that I must not worry about. When I come back from seeing that nurse, I feel nice and I
always want to visit that nurse because she’s always telling me good things.’ [26, p. 266]
d. Physician advice Personal doctor told me to stop because of medical problems including side effects of the study medication [21, p. 7]
‘‘Every time I did not understand, I asked and they made sure they explained clearly in order for me to understand
better.’’ [21, p. 4]
doi:10.1371/journal.pone.0087166.t006
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greater proportion of men (62(1) = 5.7, P= 0.017), and persons
with higher education (62(2) = 3.6, P= 0.170) [20]. Mosimaneot-
sile et al [22] and Ngamvithayapong et al [24] also found that
women were more likely to be adherent than men. Substance use
was also associated with poor adherence with Gust et al reporting
that ‘‘the case non-adherent group … had a greater proportion
of…persons who drank alcohol (62(1) = 4.4, P= 0.036) [20].
The quantitative components of the included studies typically
focus on demographic factors. Our qualitative synthesis recognises
the importance of the interaction of such demographic factors with
individual personal beliefs in influencing trends in adherence of
patients to treatment regimes [29,30,31].
Individual personal beliefs
Munseri and colleagues substantiate the subtheme relating to
fear of the side effects of INH, documenting that INH toxicity
(n = 3, 13%; peripheral neuropathy (n= 1), hepatitis (n = 2]), INH
intolerance, such as nausea (n = 4, 17%), were all reported by
participants [23]. Mindachew and colleagues found, unsurprising-
ly, that those who developed IPT related adverse effects were 93%
less likely to adhere to their prescribed doses [21]. Gust and
colleagues also found that ‘the case non adherent group … had a
greater proportion of persons who experienced any difficulty with
the regimen (62(1) = 21.9, P,0.0001)’ [20]. In this line, 22% of
participants in the study by Szakacs and colleagues agreed with the
statement, ‘‘INH is dangerous to your health’’ [26]. Munseri and
colleagues report that ‘‘Non completers were more likely to cite…
fear of INH side effects (n = 1, 14%)’’ [23].
An interesting tension emerges from the study by Munseri and
colleagues [23], whereby fear of TB itself is reported as a major
explanation for the decision to complete IPT. They observe that
an understanding of the importance of IPT (n = 35, 32%) was an
important factor: ‘‘completers were more likely to … think IPT
was important (100% vs. 87%, 95%CI 0.063–0.197, P,0.001)’’
[23]. In this context, knowledge of the importance of IPT to
successful maintenance of health may prove critical, as Szakacs
and colleagues also report that ‘‘84% agreed that without INH,
your chance of getting sick from TB is high’’ [26].
While individual personal beliefs are critical, our interpretation
is congruent with Munro et al, who emphasise interactions
between these ‘personal factors’ and factors emanating from the
other broad components, namely, socio-economic and health
service factors [27]. A similar interpretation by one of the included
studies exemplifies this assertion: In explaining the ‘paradoxical’
observation that ‘those believing they have a high or above
average chance of active TB without INH were more likely non-
adherent’, Szakacs and colleagues draw upon this concept of
interaction, stating that the influence of stigma could be one factor
interfering with the translation of patient understanding into
positive action [26].
HIV treatment and related issues
While the included studies include comparatively little quanti-
tative data on many aspects of HIV treatment, some examples
attest to the added complexity due to patients being treated for
HIV and with preventive therapy for TB at the same time. For
example, Gust and colleagues describe how ‘‘the case non-
adherent group…had greater proportion of …persons who
initiated ART (62(1) = 1.70, P = 0.192)’’ [20]. In contrast,
Mosimaneotsile and colleagues report that ‘‘those receiving ART
over the first 6 months were 1.41 fold more adherent’’ [22].
Family and other social support related factors
Quantitative evidence from the included studies also attests to
how family and other support mechanisms play a significant role
in adherence. Munseri and colleagues quantify how completers
were significantly more likely to have a family member or friend
with TB ‘‘(65% vs. 12%, 95% confidence interval (CI) 0.185–
0.875, P,0.03)’’ [23]. Furthermore, completers were ‘‘more likely
to… have family approval for their decision to take IPT (97% vs.
50%, 95% CI 0.1411–0.6389, P,0.001)’’ [23]. The spouse may
be particularly influential in instigating, or at least rationalizing,
non-adherence: ‘‘Non completers cited…spouse’s advice (n = 1,
14%)’’ [23].
Where family and social support is lacking, there is a strong
perception of stigma associated with TB. Munseri and colleagues
Figure 2. Conceptual framework of factors affecting adherence to IPT amongst PLWHA. A key interaction occurs between individual
personal beliefs and family and social support factors; where patients’ interactions with family and the wider community, including health workers
(relationships with health providers), influence their knowledge, attitudes and beliefs about IPT treatment. Socio-economic factors are likely to
influence individual personal beliefs, especially where patients live far from clinics and have fewer opportunities to be enlightened about the benefits
of IPT. Similarly, HIV treatment and related issues affect patients’ response to IPT treatment; where patients are not likely to adhere to IPT treatment if
they are not willing or able to disclose their HIV status.
doi:10.1371/journal.pone.0087166.g002
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report how a large percentage of non-completers cited ‘‘stigma
related to TB (n= 5, 58%)’’ as an important factor in their decision
to stop IPT [23]. An alternative perspective is offered by Bakari
and colleagues who explain that ‘‘…exposure or speculation about
one’s HIV status by a spouse in a married relationship can easily
be linked to extramarital sexual affairs, a fact that may culminate
in marital disharmony or even a divorce’’ [19]. The study from
Ethiopia reported that those who had ‘‘good feeling/comfortable
to take IPT drug in front of others were 6 times more likely to
adhere …’’ [21].
Socio-economic factors
Structural factors, revealed as important in the qualitative
synthesis, also occurred as explanation for adherence in the
quantitative data. Specifically, completers were more likely ‘‘to …
describe the clinic as close to their residence (72% vs. 43%, 95%CI
0.01–0.672, P,0.04)’’ [23]. Correspondingly, ‘‘non completers
cited travel distance to the clinic (n = 1, 14%)’’ [23].
Health provider related factors
Finally, adherence is facilitated by interactions with a clinician,
specifically, interactions that include counseling: ‘‘Completers
were more likely to…find counseling helpful (91% vs. 63%, 95%
CI 0.0574–0.5086, P,0.007)’’ [23]. Indeed, ‘‘patients who had
received explanation about IPT were 8 times more likely to be
adherent…’’[21].
Discussion
This systematic review assessed the available evidence regarding
factors that facilitate or hinder adherence to TB preventive
therapy amongst PLWHA. The review has accordingly drawn
upon the findings of qualitative, quantitative and mixed method
studies, while the focus lay in analysing the qualitative evidence
with use of the quantitative data to add to the comprehensiveness
of the review. We used the thematic analysis method [17,32]
which involves an analytical stage where the themes identified by
the primary studies are interpreted in light of conceptual and
theoretical understandings in the field. The analytical themes
generated in this regard, the equivalence of third order general-
isations in a meta-ethnography, go beyond mere collation of the
findings of the included studies as they are ‘the result of
interrogating a descriptive synthesis by placing it within an
external theoretical framework’ [32]. The theoretical framework
in our case is represented by the specific questions that we aimed
to satisfy through the review. It is further constructed from existing
conceptual understandings of adherence to treatment as a complex
and dynamic phenomenon that is determined by the interaction of
wide ranging factors [25,27,33].
The eight included studies specifically examine factors affecting
adherence to isoniazid as an agent of preventive therapy for TB
amongst PLWHA. In undertaking our analysis, we particularly
adopted the theoretical framework or ‘model’ developed by
Munro et al in their systematic review of factors that facilitate or
deter patients’ adherence to TB treatment [27]. Their systematic
review [27] is a generic meta-ethnography that studied both
curative and preventive treatments across general populations with
TB. Only two studies [24,25] are included in both the analyses by
Munro et al [27] and in our review. Indeed five of the remaining
reports, [20,21,22,23,26], fall outside the date range of Munro et
al’s wider systematic review (1966–February 2005) while the study
of a specific police officer population was presumably excluded
from their review for focusing on this specific population [19].
By employing meta-ethnography and undertaking third order
interpretations of the primary themes identified in the studies they
included in their review, Munro et al ‘developed a model to depict
[an] understanding of the main influences on adherence’ [27]. The
model accordingly includes four broad components, namely:
‘structural, personal, and health service factors influencing
adherence, as well as social context’ [27]. We used these broad
‘components’ to inform our categorisation of the primary themes
identified in the included primary studies whilst being sensitive to
new categorisations that emerge from analysis and translation of
the data across the included studies. Accordingly, we generated
five major, interacting themes (Figure 2), which we believe best
represent the data. These include: individual personal beliefs,
HIV/AIDS treatment related factors, socio-economic factors,
family and other support structures, and factors related to health
providers. Our review hence largely confirms the findings of the
systematic review by Munro et al [27], while highlighting and
emphasising issues found to be especially pertinent in the specific
context of adherence to a prophylactic therapy for TB patients
living with HIV/AIDS.
Socio-economic factors identified in this review, which represent
wider societal influences over which a patient has little or no
control, such as, issues related to poverty, competing social
commitments and service availability (distance to facilities and
supply of drugs), are also widely recognised as critical factors
determining patients’ health behaviour [27]. Other studies
examining adherence to HIV and TB medication in developing
countries also identify medication related costs, especially financial
costs for transport and food, and competition from other livelihood
responsibilities [34].
HIV treatment and related issues represent a critical aspect of
our analysis of factors; a theme that is especially pertinent to the
topic at hand as it reflects the complications arising from the
management/prevention of co-infection with two chronic diseases
that have multifaceted societal ramifications. The themes that
were pertinent under this broad theme are: denial of HIV status,
HIV disclosure, stigma, and attitudes towards concurrent treat-
ment of TB and HIV/AIDS. The double burden of stigma due to
TB and HIV has been documented to exacerbate and compound
the already existing stigma due to HIV in communities, whereby
individuals living with both TB and HIV are found to be more
likely to perceive stigma regarding their condition and to have very
low disease-specific knowledge, particularly with regard to its
severity [29,30].
Munseri and colleagues explain the low adherence rate for
women compared to men in their studies, stating, ‘in our setting
[Tanzania], IPT is linked to HIV, and women in this study do not
want their HIV status to be disclosed in fear of separation from
their spouses…’ [23]. This further illustrates the complex
interactions between the different major factors whereby gender
values in specific socio-cultural settings influence how stigma
attached to TB and HIV plays out to induce a differential ability of
men and women to disclose their status.
Regarding the influence of the concurrent administration of
IPT with ART, one of the included studies [22] reported a
potentiating role of ART for IPT adherence. Another study [20]
revealed patients’ perceptions of pill burden as a factor for non-
adherence. Other studies have also highlighted the potential re-
enforcing role of ART treatment programmes as they bring in
more organisation and resources in terms of counselling and
support, whereas patients would still perceive taking too many pills
as a hurdle [35,36]. This is further complicated in the case of IPT,
compared to active TB treatment, as people are generally more
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inclined to adhere to treatment when they are symptomatic than
when asymptomatic [20,25,35,36].
‘Family and other social support related factors’ are further
identified as a major theme in this review, whereby psychosocial
support from families and other social ties, the level of stigma faced
by patients as well patients’ concerns for their families have been
identified by studies as determinants of adherence trends
[23,24,25]. The medication adherence literature widely recognises
this important factor, especially when involving highly stigmatising
diseases such as HIV and TB [27,34,37].
The context of a ‘resource poor setting’ and under-developed
health systems in developing countries renders the final theme
critically important: ‘relationships with health providers’
[20,24,25,26]. Patients’ interactions with physicians and other
health service staff, such as counsellors, and the availability of
services and supply of drugs, figured prominently in our review
[20,21,23,24,25,26]. This major factor also features in reviews of
adherence to HIV and TB therapy [27,33,34].
This review is naturally constrained by limitations in the
‘‘thickness’’ of detail [38], and consequently in the depth of
analysis contained in the included primary studies. The included
studies were conducted under different contexts and do not
investigate all relevant issues in depth. For instance, interactions
between the major themes are suggested, but not always explored,
across the included studies. Also, the role of gender in mediating
stigma in societies is identified but not explored in depth. The
quantitative data reported across the studies is found to be highly
disparate; thereby not allowing the pooling and/or meta-analysis
of the results reported across the included studies. In addition, it is
not always easy to discern the authors’ interpretations from the
primary data they were reporting. Thomas and Harden state, ‘one
issue which is difficult to deal with when synthesising ‘qualitative’
studies is ‘what counts as data’ or ‘findings’?’ [32]. Also, even
though the studies were all conducted in developing countries, the
context of each study is different (well funded trials and cohort
studies versus routine services, differences in interventions, follow-
up and so on).
The implications of our review for practice are multi-fold as it
synthesises the ‘disparate’ evidence on TB preventive therapy in
PLWHA. It updates, and provides a more specific synthesis of, a
previous, generic systematic review on TB treatment in people
living with HIV/AIDS [27]. What is the value of a qualitative
systematic review of a specific preventive agent (i.e. isoniazid) for
TB in PLWHA when a generic model of adherence has already
been developed for prevention and treatment of TB in the general
population [27]? To a certain extent this debate is analogous to the
wider debate of ‘‘lumping’’ and ‘‘splitting’’ that persists for
systematic reviews as a whole [39]. Decision-makers need to
engage with evidence at the level that is most appropriate to the
decision that they are facing. Health policy makers need an overall
model of the factors to be overcome for successful implementation
of a prevent–and-treat policy. Such a generalisable model can be
provided by a meta-ethnography which makes rich use of the data
for interpretation and conceptual development. Local decision
makers also deal with specific implementation strategies, around a
specific drug such as isoniazid, in a specific population living with
HIV/AIDS. A thematic synthesis can thus identify specific factors
that need to be overcome and will typically present individual
study level data that can contribute to a greater understanding of
context. The decision-maker will therefore be interested in how
findings in their population of interest diverge from findings in a
general population facilitating identification of any factors that
require special consideration.
Our review offers several implications for research and practice.
Many of these are consonant, or indeed extend, findings from
Rowe and colleagues [25]. Interventions that may improve
adherence to latent TB and HIV/AIDS care in resource poor
settings would include provisions that facilitate attendance at the
clinics, particularly in rural areas and for those populations
requiring frequent follow up. It is clearly important to ensure that
the clinic environment is welcoming for HIV-positive patients by
maintaining confidentiality and encouraging staff to be friendly
and supportive. Previous studies conducted in Kenya and Zambia,
confirm that the poor quality of physicians’ interpersonal skills
negatively affect adherence to treatment [40,41]. One of the
limitations of this review, due to the use of patients as the primary
informants in the primary studies, is that the methodology cannot
usually identify the absence of important components such as
clinical leadership and clear policy guidelines [25]. A comple-
mentary perspective would be offered by interviewing clinical staff
delivering the services. Similarly the needs for training, supervision
and support are also latent, except where specific issues (e.g. poor
communication skills) are perceived by the patient.
Future studies need to incorporate and test existing theoretical
and conceptual understandings of adherence to TB preventive
therapy in PLWHA. They also need to seek to generate a more in-
depth understanding of how these complex factors interact with
one another. Implementation research on adherence improvement
strategies, guided by models derived from a sound conceptual
understanding of adherence, will be critical for improving the
persistently low levels of adherence to IPT amongst PLWHA.
Conclusion
Adherence to IPT in PLWHA is influenced by the interactions
of multiple factors. Accordingly, no one single strategy, such as,
patient education or financial support for patients, will help
improve adherence rates. A multi-pronged strategy that incorpo-
rates current understanding of the complexity of the interactive
factors at play and that seeks to engage patients through a holistic,
participatory and contextually tailored support is critical.
Our systematic review of the available qualitative evidence
confirms, from multiple studies across diverse contexts, that
adherence to preventive therapy for TB is:
‘‘underpinned by complex interactions between the health
service and the social, economic, and cultural environment
in which patients and their communities are immersed’’ [25]
Only by understanding this complex interplay of factors more
clearly will healthcare decision-makers be able to achieve the level
of adherence required in order to combat the threat posed by TB
in patients living with HIV and AIDS.
Supporting Information
Checklist S1 PRISMA Checklist.
(DOC)
Table S1 Ovid Medline Search Strategy.
(DOCX)
Author Contributions
Conceived and designed the experiments: TM HBT. Performed the
experiments: TM HBT AB. Analyzed the data: TM HBT AB. Wrote the
paper: TM HBT AB.
Adherence to Isoniazid Preventive Therapy
PLOS ONE | www.plosone.org 12 February 2014 | Volume 9 | Issue 2 | e87166
References
1. WHO (2011) Global Tuberculosis Control: WHO Report 2011. 2011 [cited
2012 June 21]; Available from: http://www.who.int/tb/publications/global_
report/2011/gtbr11_full.pdf.
2. Sharma SK, Mohan A, Kadhiravan T (2005) HIV-TB co-infection: epidemi-
ology, diagnosis & management. Indian J Med Res 121: 550–567.
3. Sterling TR, Pham PA, Chaisson RE (2010) HIV Infection—Related
Tuberculosis: Clinical Manifestations and Treatment. Clinical Infectious
Diseases 50: S223–S230.
4. Pawlowski A, Jansson M, Sko¨ld M, Rottenberg ME, Ka¨llenius G (2012)
Tuberculosis and HIV Co-Infection. PLoS Pathog 8: e1002464.
5. Getahun H, Gunneberg C, Granich R, Nunn P (2010) HIV Infection—
Associated Tuberculosis: The Epidemiology and the Response. Clinical
Infectious Diseases 50: S201–S207.
6. WHO IULTAD (1994) Tuberculosis preventive therapy in HIV-infected
individuals. A joint statement of the International Union Against Tuberculosis
and Lung Disease (IUATLD) and the Global Programme on AIDS and the
Tuberculosis Programme of the World Health Organization (WHO). Tuber
Lung Dis 75: 96–98.
7. WHO UNAIDS (1999) Preventive therapy against tuberculosis in people living
with HIV. Wkly Epidemiol Rec 74: 385–398.
8. WHO (2004) Interim policy on collaborative TB/HIV activities 2004 [cited
2012 June 21]; Available from: http://whqlibdoc.who.int/hq/2004/WHO_
HTM_TB_2004.330_eng.pdf.
9. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, et al. (2010)
Implementation of isoniazid preventive therapy for people living with HIV world-
wide: barriers and solutions. Aids 24: S57–S65 10.1097/1001.aids.0000391023.
0000303037.0000391021f.
10. Akolo C, Adetifa I, Shepperd S, Volmink J (2010) Treatment of latent
tuberculosis infection in HIV infected persons. Cochrane Database of Systematic
Reviews, DOI: 10.1002/14651858.CD000171.pub3.
11. De Cock KM, Grant A, Porter JDH (1995) Preventive therapy for tuberculosis
in HIV-infected persons: international recommendations, research, and practice.
The Lancet 345: 833–836.
12. Counsell C (1997) Formulating Questions and Locating Primary Studies for
Inclusion in Systematic Reviews. Annals of Internal Medicine 127: 380–387.
13. Booth A (2004) Formulating answerable questions. Evidence Based Practice: An
Information Professional’s Handbook Eds Andrew Booth and Anne Brice
London: Facet: 61–70.
14. Grant MJ (2004) How does your searching grow? A survey of search preferences
and the use of optimal search strategies in the identification of qualitative
research. Health Information & Libraries Journal 21: 21–32.
15. Flemming K, Briggs M (2007) Electronic searching to locate qualitative research:
evaluation of three strategies. Journal of Advanced Nursing 57: 95–100.
16. Hawker S, Payne S, Kerr C, Hardey M, Powell J (2002) Appraising the
Evidence: Reviewing Disparate Data Systematically. Qualitative Health
Research 12: 1284–1299.
17. Barnett-Page E, Thomas J (2009) Methods for the synthesis of qualitative
research: a critical review. BMC Medical Research Methodology 9: 59.
18. Carroll C, Booth A, Lloyd-Jones M (2012) Should We Exclude Inadequately
Reported Studies From Qualitative Systematic Reviews? An Evaluation of
Sensitivity Analyses in Two Case Study Reviews. Qualitative Health Research
22: 1425–1434.
19. Bakari M, Moshi A, Aris E, Chale S, Josiah R, et al. (2000) Isoniazid prophylaxis
for tuberculosis prevention among HIV infected police officers in Dar es Salaam.
East African medical journal 77.
20. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, et al. (2011)
Risk Factors for Non-Adherence and Loss to Follow-Up in a Three-Year
Clinical Trial in Botswana. PLoS ONE 6: e18435.
21. Mindachew M, Deribew A, Tessema F, Biadgilign S (2011) Predictors of
adherence to isoniazid preventive therapy among HIV positive adults in Addis
Ababa, Ethiopia. BMC Public Health 11: 1–7.
22. Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, et al.
(2010) Isoniazid Tuberculosis Preventive Therapy in HIV-Infected Adults
Accessing Antiretroviral Therapy: A Botswana Experience, 2004–2006. JAIDS
Journal of Acquired Immune Deficiency Syndromes 54: 71–77 10.1097/
QAI.1090b1013e3181c1093cbf1090.
23. Munseri PJ, Talbot EA, Mtei L, Fordham von Reyn C (2008) Completion of
isoniazid preventive therapy among HIV-infected patients in Tanzania. The
International Journal of Tuberculosis and Lung Disease 12: 1037–1041.
24. Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P
(1997) Adherence to tuberculosis preventive therapy among HIV-infected
persons in Chiang Rai, Thailand. Aids 11: 107–112.
25. Rowe KA, Makhubele B, Hargreaves JR, Porter JD, Hausler HP, et al. (2005)
Adherence to TB preventive therapy for HIV-positive patients in rural South
Africa: implications for antiretroviral delivery in resource-poor settings? The
International Journal of Tuberculosis and Lung Disease 9: 263–269.
26. Szakacs T, Wilson D, Cameron DW, Clark M, Kocheleff P, et al. (2006)
Adherence with isoniazid for prevention of tuberculosis among HIV-infected
adults in South Africa. BMC Infectious Diseases 6: 97.
27. Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, et al. (2007) Patient
Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative
Research. PLoS Med 4: e238.
28. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, et al. (2006) Guidance on
the conduct of narrative synthesis in systematic reviews. A product from the
ESRC methods programme Version 1.
29. Deribew A, HaileMichael Y, Tesfaye M, Desalegn D, Wogi A, et al. (2010) The
synergy between TB and HIV co-infection on perceived stigma in Ethiopia.
BMC Research Notes 3: 249.
30. Jittimanee SX, Nateniyom S, Kittikraisak W, Burapat C, Akksilp S, et al. (2009)
Social Stigma and Knowledge of Tuberculosis and HIV among Patients with
Both Diseases in Thailand. PLoS ONE 4: e6360.
31. Shieh FK, Snyder G, Robert Horsburgh C, Bernardo J, Murphy C, et al. (2006)
Predicting Non-Completion of Treatment for Latent Tuberculous Infection.
American Journal of Respiratory and Critical Care Medicine 174: 717–721.
32. Thomas J, Harden A (2008) Methods for the thematic synthesis of qualitative
research in systematic reviews. BMC Medical Research Methodology 8: 45.
33. Martin LR, Williams SL, Haskard KB, DiMatteo MR (2005) The challenge of
patient adherence. Therapeutics and clinical risk management 1: 189.
34. Wasti SP, van Teijlingen E, Simkhada P, Randall J, Baxter S, et al. (2012)
Factors influencing adherence to antiretroviral treatment in Asian developing
countries: a systematic review. Tropical Medicine & International Health 17:
71–81.
35. Amuha MG, Kutyabami P, Kitutu FE, Odoi-Adome R, Kalyango JN (2009)
Non-adherence to anti-TB drugs among TB/HIV co-infected patients in
Mbarara Hospital Uganda: Prevalence and associated factors. African health
sciences 9.
36. Jaiswal A, Singh V, Ogden JA, Porter JDH, Sharma PP, et al. (2003) Adherence
to tuberculosis treatment: lessons from the urban setting of Delhi, India. Tropical
Medicine & International Health 8: 625–633.
37. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C (2000) The relationship
of disease severity, health beliefs and medication adherence among HIV
patients. AIDS Care 12: 387–398.
38. Morse JM (1995) The Significance of Saturation. Qualitative Health Research 5:
147–149.
39. Weir MC, Grimshaw JM, Mayhew A, Fergusson D (2012) Decisions about
lumping vs. splitting of the scope of systematic reviews of complex interventions
are not well justified: A case study in systematic reviews of health care
professional reminders. Journal of Clinical Epidemiology 65: 756–763.
40. Bartlett EE, Grayson M, Barker R, Levine DM, Golden A, et al. (1984) The
effects of physician communications skills on patient satisfaction; recall, and
adherence. Journal of chronic diseases 37: 755–764.
41. Dunbar J (2004) Predictors of patient adherence: patient characteristics, in The
Handbook of Health Behaviour Change, Shumaker S, Schroon E, Ockene J,
Editors. 2004, Springer New York. p. 348–360.
Adherence to Isoniazid Preventive Therapy
PLOS ONE | www.plosone.org 13 February 2014 | Volume 9 | Issue 2 | e87166
